Immunicon: trial meets endpoints, company to partner with MolMed

By Lisa Kerner

Charlotte, N.C., Sept. 28 - Immunicon Corp.'s trial in pivotal metastatic colorectal cancer met its primary and secondary endpoints, said president and chief executive officer Byron D. Hewett in comments made Thursday at the UBS Global Life Sciences Conference in New York.

Hewett also announced Immunicon's research and laboratory services agreement with MolMed SpA.

The primary endpoint of the prospective, multicenter trial was agreement between the number of circulating tumor cells (CTCs) and response to therapy as measured by imaging 6 to 12 weeks after the start of therapy.

Secondary endpoint was the number of CTCs prior to and after the start of therapy as predictors of progression-free survival and overall survival.

Immunicon and the Italian pharmaceutical company MolMed plan to develop a biomarker for tumor endothelial cells for drug development. The Laboratory Services Agreement calls for analysis of CTCs and circulating endothelial cells in a phase 2 dose-escalation trial.

Hewett also noted that the current cash burn guidance is $20 million to $24 million, compared to cash burn of $48 million in 2004 and $27.5 million in 2005.

Immunicon is a life science research company located in Huntingdon Valley, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.